Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Lakeside Vision Center

Neither a doctor nor a teaching hospital

Research payments

$363,578

68 payments

Through program year 2025, Lakeside Vision Center is reported as receiving $363,578 in research payments, across 68 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $40,482 7
2024 Research $31,442 3
2023 Research $152,253 8
2022 Research $92,398 12
2021 Research $32,210 5
2020 Research $3,026 19
2019 Research $11,766 14

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $150,480 23 payments
  2. Ocular Therapeutix, Inc. $143,766 2 payments
  3. Padagis US LLC $32,040 4 payments
  4. Allergan Inc. $29,263 34 payments
  5. Sight Sciences, Inc. $5,530 4 payments
  6. Perrigo Company plc $2,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) $143,766 2 payments
  2. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $45,177 11 payments
  3. Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension $33,033 2 payments
  4. Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Brimonidine Ophthalmic Suspension 1 percent to Simbrinza in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes $32,040 4 payments
  5. A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension $23,424 1 payment
  6. Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $20,403 3 payments
  7. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $14,470 1 payment
  8. A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $11,237 1 payment
  9. 1833-201-407 Ph2 Clinical Study (M21-467) $11,084 1 payment
  10. A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment $7,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record